- Selected Publications
- Team Members
- Curriculum Vitae
Gregory Carr, Ph.D. is an Investigator in the Drug Discovery Division of the Lieber Institute and an Assistant Professor in the Johns Hopkins University School of Medicine Department of Pharmacology and Molecular Sciences. Dr. Carr leads the in vivo pharmacology research group with the goal of identifying novel therapeutics for the treatment of neurological and psychiatric disorders. Dr. Carr received a BA in Neuroscience from Kenyon College and his PhD in Neuroscience from the University of Pennsylvania. Prior to joining the Lieber Institute, Dr. Carr was a postdoctoral fellow in the Clinical Brain Disorders Branch of the National Institute of Mental Health and an adjunct instructor in the Department of Biology at Howard University.
Psychiatric disorders and related neurodevelopmental disorders result from the complex interaction of multiple genetic and environmental risk factors. Our laboratory uses rodent models to determine how these risk factors modulate neurobiology and behavior. We utilize neurochemical, electrophysiological, and behavioral assays to interrogate the neural systems thought to be abnormal in neurodevelopmental disorders. Our ultimate goal is to use this knowledge to inform drug discovery efforts designed to increase and improve the treatment options available for central nervous system disorders. We also conduct research focused on developing novel behavioral assays with increased translational value for screening novel therapeutics.
Carr GV*, Jenkins KA*, Weinberger DR, Papaleo F. Loss of dysbindin‐1 in mice impairs reward‐based operant learning by increasing impulsive and compulsive behavior. Behavioural Brain Research. 241: 173-184, 2013.
Carr GV, Schechter LE, Lucki I. Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists. Psychopharmacology. 213 (2-3): 499-507, 2011.
Carr GV, Lucki I. The role of serotonin receptor subtypes in treating depression: A review of animal studies. Psychopharmacology. 213 (2-3): 265-287, 2011.
Carr GV, Lucki I. Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats. Psychopharmacology. 210 (2): 295-302, 2010.
Carr GV, Bangasser DA, Bethea T, Young M, Valentino RJ, Lucki I. Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacology. 35 (3): 752-763, 2010.
*These authors contributed equally to this work.
LIBD Speaker Series: Kathleen Ries Merikangas, Ph.D.
Title coming soon Kathleen Ries Merikangas, Ph.D. Senior Investigator & Chief, Genetic Epidemiology Research Unit Intramural Research Program National Institute of Mental Health When: April 21, 2020 2:00pm-3:00pm Where: The Lieber Institute for Brain Development Rangos Building Main Conf. Room Suite 300 […]